BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23502212)

  • 1. Molecular determinants for nuclear receptors selectivity: chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors α/γ agonists.
    Carrieri A; Giudici M; Parente M; De Rosas M; Piemontese L; Fracchiolla G; Laghezza A; Tortorella P; Carbonara G; Lavecchia A; Gilardi F; Crestani M; Loiodice F
    Eur J Med Chem; 2013 May; 63():321-32. PubMed ID: 23502212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors α/γ dual agonists.
    Fracchiolla G; Laghezza A; Piemontese L; Parente M; Lavecchia A; Pochetti G; Montanari R; Di Giovanni C; Carbonara G; Tortorella P; Novellino E; Loiodice F
    Bioorg Med Chem; 2012 Mar; 20(6):2141-51. PubMed ID: 22341573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
    Pinelli A; Godio C; Laghezza A; Mitro N; Fracchiolla G; Tortorella V; Lavecchia A; Novellino E; Fruchart JC; Staels B; Crestani M; Loiodice F
    J Med Chem; 2005 Aug; 48(17):5509-19. PubMed ID: 16107150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
    Fracchiolla G; Laghezza A; Piemontese L; Tortorella P; Mazza F; Montanari R; Pochetti G; Lavecchia A; Novellino E; Pierno S; Conte Camerino D; Loiodice F
    J Med Chem; 2009 Oct; 52(20):6382-93. PubMed ID: 19775169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.
    Batista FA; Trivella DB; Bernardes A; Gratieri J; Oliveira PS; Figueira AC; Webb P; Polikarpov I
    PLoS One; 2012; 7(5):e33643. PubMed ID: 22606221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype.
    Kuwabara N; Oyama T; Tomioka D; Ohashi M; Yanagisawa J; Shimizu T; Miyachi H
    J Med Chem; 2012 Jan; 55(2):893-902. PubMed ID: 22185225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α/γ.
    dos Santos JC; Bernardes A; Giampietro L; Ammazzalorso A; De Filippis B; Amoroso R; Polikarpov I
    J Struct Biol; 2015 Sep; 191(3):332-40. PubMed ID: 26185032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
    Gani OA
    Cardiovasc Diabetol; 2008 Mar; 7():6. PubMed ID: 18355413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular determinants for improved activity at PPARα: structure-activity relationship of pirinixic acid derivatives, docking study and site-directed mutagenesis of PPARα.
    Lamers C; Dittrich M; Steri R; Proschak E; Schubert-Zsilavecz M
    Bioorg Med Chem Lett; 2014 Aug; 24(16):4048-52. PubMed ID: 25022880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
    Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
    J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach.
    D'Aniello E; Fellous T; Iannotti FA; Gentile A; Allarà M; Balestrieri F; Gray R; Amodeo P; Vitale RM; Di Marzo V
    Biochim Biophys Acta Gen Subj; 2019 Mar; 1863(3):586-597. PubMed ID: 30611848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator.
    Seethala R; Golla R; Ma Z; Zhang H; O'Malley K; Lippy J; Cheng L; Mookhtiar K; Farrelly D; Zhang L; Hariharan N; Cheng PT
    Anal Biochem; 2007 Apr; 363(2):263-74. PubMed ID: 17335769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The conserved residue Phe273(282) of PPARalpha(gamma), beyond the ligand-binding site, functions in binding affinity through solvation effect.
    Yue L; Ye F; Xu X; Shen J; Chen K; Shen X; Jiang H
    Biochimie; 2005 Jun; 87(6):539-50. PubMed ID: 15935279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative structure-activity relationship models with receptor-dependent descriptors for predicting peroxisome proliferator-activated receptor activities of thiazolidinedione and oxazolidinedione derivatives.
    Lather V; Kairys V; Fernandes MX
    Chem Biol Drug Des; 2009 Apr; 73(4):428-41. PubMed ID: 19243388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel PPARα/γ dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations.
    Liu X; Jing Z; Jia WQ; Wang SQ; Ma Y; Xu WR; Liu JW; Cheng XC
    J Biomol Struct Dyn; 2018 Aug; 36(11):2988-3002. PubMed ID: 28853334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from traditional Chinese medicine.
    Chen KC; Chang SS; Huang HJ; Lin TL; Wu YJ; Chen CY
    J Biomol Struct Dyn; 2012; 30(6):662-83. PubMed ID: 22731403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New 2-(aryloxy)-3-phenylpropanoic acids as peroxisome proliferator-activated receptor α/γ dual agonists able to upregulate mitochondrial carnitine shuttle system gene expression.
    Laghezza A; Pochetti G; Lavecchia A; Fracchiolla G; Faliti S; Piemontese L; Di Giovanni C; Iacobazzi V; Infantino V; Montanari R; Capelli D; Tortorella P; Loiodice F
    J Med Chem; 2013 Jan; 56(1):60-72. PubMed ID: 23171045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and evaluation of 2,3-dinorprostaglandins: Dinor-PGD1 and 13-epi-dinor-PGD1 are peroxisome proliferator-activated receptor α/γ dual agonists.
    Sato A; Dodo K; Makishima M; Hashimoto Y; Sodeoka M
    Bioorg Med Chem Lett; 2013 May; 23(10):3013-7. PubMed ID: 23566516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
    Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
    Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.